Physician profile
Tamara S Smith
NPI 1225127129
$1,314.35
in general payments reported to CMS, 2019-2025
15 companies · $31.14 in 2025
The $31.14 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $148 · 2021: $191 · 2022: $209 · 2023: $324 · 2024: $143 · 2025: $31.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $239.28 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $182.49 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $178.68 | 2019-2024 | Tezspire, Fasenra, Airsupra |
| Kaleo, INC. | $178.09 | 2019-2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $129.36 | 2020-2024 | Takhzyro |
| Glaxosmithkline, LLC. | $111.12 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $64.32 | 2019-2024 | Dupixent |
| Biocryst US Sales Co., LLC | $61.31 | 2022-2023 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $39.99 | 2019-2024 | |
| Pfizer INC. | $37.61 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $30.04 | 2023 | Ryaltris |
| Incyte Corporation | $16.28 | 2024 | Opzelura |
| Alk-Abello, INC | $16.11 | 2020 | |
| Amgen INC. | $15.03 | 2024 | Tezspire |
| Greer Laboratories, INC. | $14.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.